Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2008

Response Genetics Creates Sales Strategy for Its ResponseDX Tests

  • Response Genetics is enhancing its sales strategy for its prognostic tests for colon and lung cancers. It has formed an in-house sales team and exclusively signed on NeoGenomics as an authorized national clinical reference laboratory.

    ResponseDX: Colon™ and ResponseDX: Lung™ are designed to help with treatment decisions for patients with non-small-cell lung cancer and colorectal cancer. These PCR-based panels include three key genes: ERCC1, TS and EGFR. The tests also include the analysis of K-ras gene mutations, which is a strong predictor of nonresponse and no benefit from the epidermal growth factor receptor inhibitors.

    Response Genetics was unavailable to comment on the current uptake of the tests. In March, the firm made ResponseDX: Colon and ResponseDX: Lung available to select medical institutions and practice groups through its CLIA-registered laboratory.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »